{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:54:44Z","timestamp":1720745684097},"reference-count":12,"publisher":"Georg Thieme Verlag KG","issue":"S 01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Res (Stuttg)"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1055\/a-1606-5858","type":"journal-article","created":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T23:54:33Z","timestamp":1637193273000},"page":"S16-S18","source":"Crossref","is-referenced-by-count":0,"special_numbering":"S","title":["Nichtalkoholische Steatohepatitis (NASH) und alkoholische Steatohepatitis (ASH)"],"prefix":"10.1055","volume":"71","author":[{"given":"Elke","family":"Roeb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2021,11,17]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: a multisystem disease","volume":"62","author":"C D Byrne","year":"2015","journal-title":"J Hepatol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s00125-016-3910-y","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: is universal screening appropriate?","volume":"59","author":"C D Byrne","year":"2016","journal-title":"Diabetologia"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL\u2013EASD\u2013EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","author":"European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD)","year":"2016","journal-title":"J Hepatol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"S L Friedman","year":"2018","journal-title":"Nat Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1136\/gutjnl-2017-315691","article-title":"Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation","volume":"67","author":"S H Ibrahim","year":"2018","journal-title":"Gut"},{"key":"ref6","first-page":"76","volume-title":"Fettleber","author":"E Roeb","year":"2019"},{"key":"ref7","first-page":"668","article-title":"[S2\u2009k Guideline non-alcoholic fatty liver disease]","volume":"53","author":"E Roeb","year":"2015","journal-title":"Z Gastroenterol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"A J Sanyal","year":"2010","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1210\/jc.2013-1519","article-title":"Resolution of fatty liver and risk of incident diabetes","volume":"98","author":"K C Sung","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jhep.2017.09.016","article-title":"Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine","volume":"68","author":"N Fujiwara","year":"2018","journal-title":"J Hepatol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1055\/a-0784-8827","article-title":"Nonalcoholic steatohepatitis (NASH) \u2013 current treatment recommendations and future developments","volume":"57","author":"E Roeb","year":"2019","journal-title":"Z Gastroenterol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"Easl Clinical Practice Guidelines (Cpgs) On Non-Invasive Tests For Evaluation Of Liver Disease Severity And Prognosis \u2013 2020\u2009Update","volume":"75","author":"European Association for the Study of the Liver","year":"2021","journal-title":"J Hepatol"}],"container-title":["Drug Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1606-5858.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T23:55:33Z","timestamp":1637193333000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1606-5858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":12,"journal-issue":{"issue":"S 01","published-online":{"date-parts":[[2021,11,17]]},"published-print":{"date-parts":[[2021,11]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1606-5858","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2194-9379","2194-9387"],"issn-type":[{"value":"2194-9379","type":"print"},{"value":"2194-9387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11]]}}}